-transparent.png){kind=logo}
Oxybutynin hydrochloride (3 mg) was compared with placebo by randomised, double-blind crossover trial in 53 females with idiopathic detrusor instability. Symptoms were cured or markedly improved in 60% of patients on oxybutynin and 2.3% on placebo. During the first treatment period, oxybutynin reduced the frequency of voiding by 35%, compared with 9% for placebo. Oxybutynin gave a significantly greater improvement than placebo in volume at the first desire to void (70 ml increase versus 7.7 ml), maximum filling-phase detrusor pressure (17 cm H2O reduction versus no benefit) and cystometric capacity (104 ml increase versus 7.0 ml). A marked oxybutynin carry-over effect was seen during the second treatment period. Side effects from the 3 mg dose of oxybutynin caused 7.5% of subjects to discontinue therapy.
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
January 1990,
International urology and nephrology,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
November 1995,
British journal of obstetrics and gynaecology,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
March 1979,
Southern medical journal,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
January 1998,
International urogynecology journal and pelvic floor dysfunction,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
January 1986,
Actas urologicas espanolas,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
January 1990,
Actas urologicas espanolas,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
May 2002,
Saudi medical journal,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
May 1988,
Drug and therapeutics bulletin,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
January 1985,
Urologia internationalis,
K H Moore, and
D M Hay, and
A E Imrie, and
A Watson, and
M Goldstein
January 1977,
Urologia internationalis,
